Ultime notizie per Myomo (AMEX:MYO) Azioni

MYOMO INC

Myomo

Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).

Myomo Inc

WIIM

BITF

CLSK

COIN

MARA

MSTR

RIOT

Shares of Bitcoin miners and crypto-linked stocks are trading lower amid a drop in Bitcoin as market uncertainty persists.

Barclays analyst Brandon Oglenski maintains Allegiant Travel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGT#NASDAQ">ALGT</a>) with a Equal-Weight and lowers the price target from $100 to $60.

News

Price Target

Analyst Ratings

ALGT

Barclays Maintains Equal-Weight on Allegiant Travel, Lowers Price Target to $60

JPMorgan analyst Jeremy Tonet sees utility companies relatively well-positioned amid concerns that recent tariff hikes could trigger <a href="https://www.benzinga.com/topic/recession">a global recession</a>.
What Happened: JPMorgan projects a -0.3%<a href="https://www.benzinga.com/topic/macro-economic-events" target="_blank" rel="noreferrer noopener"> U.S. GDP contraction in 2025</a>.
Maia G. Crook, also a JPMorgan analyst, says the probability of a U.S. recession has surged to 60%. That&#8217;s up from 40% last month, due to <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44645681/jpmorgan-raises-recession-risk-to-60-as-largest-us-tax-hike-in-60-years-hits-global-economy" target="_blank" rel="noreferrer noopener">the latest round of tariff hikes</a>.
The analysts&#8217; view on utilities reflects the sector&#8217;s regulated return profile and cost-of-service structure, which insulate them from direct tariff-related EPS impacts.
Moreover, potential rate cuts may further boost their income appeal.
Meanwhile, Tonet says that prolonged tariff uncertainty could harm sentiment and the broader economy, creating affordability challenges that may impact utilities' capex plans and returns, especially in regions with tight energy supply.
Tonet downgraded Dominion Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>) from Neutral to Underweight and cut the <a href="https://www.benzinga.com/quote/d/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from $59 to $52</a>.
The company&#8217;s Coastal Virginia Offshore Wind (CVOW) project faces increased risks with $2.5 billion in remaining non-US spending and potential steel/EU/Mexico tariff impacts, which could add $500 million-$625 million in costs.
Combined with still-to-be-finalized PJM network upgrades (+$600 million), these factors pose external challenges, adds the analyst.
Moreover, the analyst writes that administration support for offshore wind seems to be uncertain, adding to concerns.
On the other hand, Tonet raised the rating for WEC Energy Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>) from Underweight to Neutral and the <a target="_blank" href="https://www.benzinga.com/quote/wec/analyst-ratings" rel="noreferrer noopener">price forecast from $106 to $108</a>.
Tonet says that WEC stands out due to its lack of rate case exposure and favorable regulatory environment in Wisconsin.
The company is well-positioned as a defensive stock, benefiting from regulatory stability and potential upside from projects like MSFT/Cloverleaf data centers, adds the analyst.
Also, the analyst upgraded Southern Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>) from Underweight to Neutral while <a target="_blank" href="https://www.benzinga.com/quote/so/analyst-ratings" rel="noreferrer noopener">maintaining the price forecast at $94</a>.
The analyst writes that SO stands out within utility coverage for its strong regulatory environment, solid balance sheet, large scale, and economic resilience in its service area.
However, ongoing regulatory uncertainty tied to the Georgia Power rate case limits immediate upside, adds the analyst.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44694248/rpm-q3-weather-foreign-currency-and-lower-demand-weigh-on-performance-guidance-sees-modest-growth-ahead" target="_blank" rel="noreferrer noopener">RPM Q3: Weather, Foreign Currency, and Lower Demand Weigh on Performance, Guidance Sees Modest Growth Ahead</a></li>
</ul>
Image: Shutterstock

Equities

Large Cap

Mid Cap

Upgrades

Downgrades

Recession Risk Is High, But Analysts Say This Sector Is Shielded From Tariff Impact

Barclays analyst Brandon Oglenski maintains Alaska Air Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) with a Overweight and lowers the price target from $80 to $62.

Barclays Maintains Overweight on Alaska Air Gr, Lowers Price Target to $62

Wall Street's early rally lost steam and flipped into negative territory Tuesday afternoon after White House Press Secretary Karoline Leavitt confirmed that President Donald Trump's retaliatory 104% tariff on Chinese imports would take <a href="https://www.benzinga.com/topic/donald-trump">effect at 12:01 a.m. ET Wednesday. </a>
Her remarks triggered a sharp deterioration in market sentiment and reignited fears of a global trade escalation.
By 2:15 p.m. ET, the S&amp;P 500 – as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – had slipped 0.3%, the Russell 2000 fell 1.3%, and the Nasdaq 100 was barely positive, up just 0.1%. The Dow Jones Industrial Average held onto a 0.3% gain, though upside momentum was fading fast.
<h3 class="wp-block-heading">What Triggered The Market Turnaround?</h3>
Leavitt&#8217;s remarks delivered clarity — and a hard deadline — for Trump&#8217;s escalating tariff campaign.
"There will be 104% tariffs going into effect on China tonight at midnight," Leavitt said. 
"It was a mistake for China to retaliate, and the president is punching back harder."
The press secretary echoed Trump&#8217;s hardline stance, stating that "America does not need other countries as much as other countries need us," and emphasized that the president believes China wants to make a deal, but doesn't know how to start.
While earlier this week Trump hinted at openness to negotiations, Tuesday's update suggested no de-escalation in sight.
Leavitt insisted that tariffs are not up for delay or exemption, rejecting suggestions that market turmoil had prompted a policy shift. 
She confirmed that the administration expects these trade deals and tariffs to generate "trillions of dollars in revenue" while incentivizing onshoring and closing U.S. trade deficits.
Earlier on Tuesday, Chicago Fed President Austan Goolsbee warned that the economic consequences of tariffs may already be materializing.
"We can't wait until the end of the quarter plus one month to find out that investment has dropped off and GDP growth is shrinking," Goolsbee said, calling for timelier insight into the drag from protectionist policy.
<h3 class="wp-block-heading">Tech Stocks Lose Steam, Semis Cool Off</h3>
After leading the rally earlier in the session, tech stocks began to falter. 
Among the Magnificent Seven, Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) turned sharply lower, down 2.33%, while Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shed 0.85% and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) slipped 0.32%.
Only Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) continued to hold onto gains, up 2.43%.
Semiconductor stocks, which had gained over 3.3% by midday, then flipped to losses, with the iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) down 0.4%.
Defensive sectors such as utilities and communications hovered near flat, while materials and consumer discretionary posted the steepest losses amid fears of disrupted global supply chains.
Read now: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44674785/trump-vows-to-reset-global-trade-warns-iran-faces-great-danger-if-talks-fail">Trump Vows To &#8216;Reset&#8217; Global Trade, Warns Iran Faces &#8216;Great Danger&#8217; If Talks Fail</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Broad U.S. Equity ETFs

Economics

Tech

ETFs

AAPL

AMZN

NVDA

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

TSLA

Markets Reverse Gains As Trump's 104% China Tariff Announcement Rattles Wall Street

Shares of major European indexes are trading higher after the US and China announced retaliatory tariffs directed at each other, which may redirect greater trade flows to the EU region. Additionally, European indexes may be trending higher on the continuation of capital flows rotating out of American equities year-to-date.

Barclays analyst Matthew Bouley maintains Trex Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) with a Underweight and lowers the price target from $67 to $54.

TREX

Barclays Maintains Underweight on Trex Co, Lowers Price Target to $54

Barclays analyst Matthew Bouley maintains Toll Brothers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) with a Underweight and lowers the price target from $101 to $92.

Barclays Maintains Underweight on Toll Brothers, Lowers Price Target to $92

Barclays analyst Matthew Bouley maintains AZEK Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>) with a Overweight and lowers the price target from $64 to $53.

AZEK

Barclays Maintains Overweight on AZEK Co, Lowers Price Target to $53

Barclays analyst Matthew Bouley maintains Taylor Morrison Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMHC#NYSE">TMHC</a>) with a Overweight and lowers the price target from $90 to $70.

TMHC

Barclays Maintains Overweight on Taylor Morrison Home, Lowers Price Target to $70

Barclays analyst Matthew Bouley maintains SiteOne Landscape Supply (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SITE#NYSE">SITE</a>) with a Underweight and lowers the price target from $120 to $106.

SITE

Barclays Maintains Underweight on SiteOne Landscape Supply, Lowers Price Target to $106

<a href="https://www.youtube.com/live/Z1ZTlURVm94?si=-6lmaGc44N_4EOnQ" title="https://www.youtube.com/live/Z1ZTlURVm94?si=-6lmaGc44N_4EOnQ">https://www.youtube.com/live/Z1ZTlURVm94?si=-6lmaGc44N_4EOnQ</a>

Politics

General

Fed's Daly Says Fed Policy In A Very Good Place; Says Modestly Restrictive; Says We've Time To Tread Slowly, Carefully On Policy

Barclays analyst Matthew Bouley maintains PulteGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>) with a Equal-Weight and lowers the price target from $117 to $100.

Barclays Maintains Equal-Weight on PulteGroup, Lowers Price Target to $100

Barclays analyst Matthew Bouley maintains Owens-Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) with a Overweight and lowers the price target from $215 to $179.

Barclays Maintains Overweight on Owens-Corning, Lowers Price Target to $179

Spruce Point Capital Management&nbsp;has announced a short position against Monster Beverage Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>) as the short seller sees <a href="https://www.benzinga.com/quote/MNST">25% to 40% downside risk</a>.
What To Know: After conducting a forensic financial and accounting review, <a href="https://www.benzinga.com/topic/short-sellers">short seller</a> Spruce Point raised concerns about the sustainability of Monster&#8217;s recent financial performance and the accuracy of its accounting and financial reporting in a new short report released Tuesday. 
&#8220;Changing consumer preferences, an evolving regulatory landscape, and pressures to reduce government supported programs for unhealthy foods leaves Monster vulnerable to escalating threats,&#8221; the short seller said.
&#8220;We believe Monster is likely aware of these challenges and is acting in a manner to combat these issues. However, we also believe that Monster may be taking aggressive and/or non-transparent actions that are not in the best interests of investors.&#8221;
Benzinga has reached out to Monster Beverage for comment on the report. 
Spruce Point believes Monster Beverage shares are fully valued and offer poor risk/reward from current levels. The short seller noted that insiders have been accelerating their pace of stock sales and more than 50% of analysts don&#8217;t have a &#8220;Buy&#8221; rating on the stock.
Monster also trades with an &#8220;irrational&#8221; premium compared to Coca-Cola Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) despite being highly dependent on the company for distribution, the short seller said. Monster has a price-to-earnings ratio of approximately 30.8, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. Meanwhile, Coca-Cola trades with a price-to-earnings ratio of approximately 20. 
Furthermore, Spruce Point alleged that Monster&#8217;s relationship with Coke is &#8220;not healthy&#8221; and a potential takeover deal is not in the cards. The short seller said it uncovered evidence of a financial strain between the two companies starting in 2022. 
Check This Out: <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44697600/stocks-rebound-chipmakers-soar-on-trade-deal-hopes-bitcoin-lags-whats-driving-markets-tuesday#google_vignette">Stocks Rebound, Chipmakers Soar On Trade Deal Hopes, Bitcoin Lags: What&#8217;s Driving Markets Tuesday?</a>
Spruce Point also said it takes issue with how Monster is reporting sales for its Tour Water brand. Although it&#8217;s not an energy drink product, the company reported its revenue in the Monster Energy Drinks segment, which could &#8220;potentially be a lever to inflate energy drink organic sales.&#8221;
&#8220;Moreover, Monster says it is distributed through the Alcohol Brands segment, which casts further doubt on the soundness of its revenue recognition choice,&#8221; the short seller said. 
Spruce Point went on to raise concerns around margins on sales through Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), production inefficiencies, increasing competition and social media brand stagnation. 
Spruce Point issued a &#8220;Strong Sell&#8221; opinion on Monster shares as the short seller expects Monster to underperform the food and beverage industry along with the broader equity market moving forward. 
MNST Price Action: <a href="http://benzinga.com/quote/mnst">Monster Beverage shares</a> were down 2.6% at $55.60 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44696168/apple-is-a-buying-opportunity-again-as-key-valuation-level-flashes-green-bank-of-america-says">Apple Is A &#8216;Buying Opportunity&#8217; Again As Key Valuation Level Flashes Green, Bank Of America Says</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/nawawi+mohamed">kiraziku2u</a>/Shutterstock.

Short Sellers

Short Ideas

Trading Ideas

MNST

Short Seller Sees 25% To 40% Downside In Monster Beverage Shares: 'Vulnerable To Escalating Threats'

ACDC

CLMT

CSAN

FANG

KLXE

Shares of energy companies are trading lower possibly amid ongoing weakness after crude levels dropped to 2021 levels following OPEC+'s decision to accelerate production hikes. Also, the industry may be declining due to global tensions related to US-China retaliatory tariffs.

Global

Federal Reserve

Fed's Daly Says CEOs Feel Uncertain; Says Businesses Are Optimistic About Growth; Says People Move Through Uncertainty, There's Resilience And Agility; Says  A Little Concerned Inflation May Pick Back Up From Tariffs; Says Uncertainty We Have Now Can Be Worked Through; Says Important To Stay Steady, Think About Net Effect Of Administration's Slate Of Changes; Says Don't Have Complete Clarity On Tariffs

Barclays analyst Matthew Bouley maintains Mohawk Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>) with a Equal-Weight and lowers the price target from $125 to $115.

Barclays Maintains Equal-Weight on Mohawk Industries, Lowers Price Target to $115

Barclays analyst Matthew Bouley maintains Masco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) with a Overweight and lowers the price target from $87 to $75.

Barclays Maintains Overweight on Masco, Lowers Price Target to $75

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) on Tuesday announced results from additional analyses of the Phase 3 Vivacity-MG3 study and the ongoing open-label extension&nbsp;(OLE), evaluating the long-term efficacy and safety of nipocalimab in a broad population of antibody-positive adults with <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">generalized myasthenia gravis (gMG)</a>.
Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their MG-ADL (activities of daily living)&nbsp;and QMG (quantifies disease severity)&nbsp;scores over 84 weeks with sustained reductions <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44678645/johnson-johnson-highlights-new-data-that-showcase-the-strength-of-nipocalimab-demonstrating-long-t" rel="noreferrer noopener">in total immunoglobulin G (IgG)</a>.
Nipocalimab demonstrated a mean change in MG-ADL of -5.64 (p&lt;0.001) after 60 weeks in the OLE for study participants receiving nipocalimab and SOC, and -6.01 (p&lt;0.001) mean change&nbsp;for study participants who transitioned from placebo and SOC to nipocalimab and SOC.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44651117/johnson-johnsons-tremfya-shows-efficacy-across-multiple-domains-in-late-stage-psoriatic-arthritis-study" rel="noreferrer noopener">Johnson &amp; Johnson&#8217;s Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study</a>
In the antibody-positive population, 45%&nbsp;of patients receiving steroids at the OLE baseline were able to decrease or discontinue steroids at the time of this data cut by more than half of the baseline dose.
<ul>
<li>Among these patients, the mean dose of prednisone decreased from 23 to 10&nbsp;mg daily.</li>
</ul>
Nipocalimab had a consistent and tolerable safety profile throughout the OLE phase.
Additional findings from the Phase 3 Vivacity-MG3 study indicate that patients treated with nipocalimab plus SOC achieved statistically significant improvements in their QMG score by -4.9 versus placebo plus SOC (p&lt;0.001) over weeks 22 and 24.
Patients in the nipocalimab plus SOC treatment group were four times more likely to sustain symptom improvement at 20 weeks than the placebo plus SOC group, as measured by a three- or greater-point improvement on the QMG score.
Results show significantly more patients treated with nipocalimab (36.4%) versus placebo (10.5%, p&lt;0.001) spent greater than 75% of the study duration, demonstrating improvements in the QMG score.
A reduction of more than three points in the QMG score indicates a decrease in the severity of the patient&#8217;s symptoms due to improvements in muscle strength, allowing patients to carry out important daily activities such as swallowing and chewing.
Price Action: JNJ stock is down 0.21% at $150.31 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/44695622/amazon-touts-ai-milestone-says-new-model-outshines-gpt-4o-in-real-time-speech" target="_blank" rel="noreferrer noopener">Amazon Touts AI Milestone, Says New Model Outshines GPT-4o In Real-Time Speech</a></li>
</ul>
Image via Shutterstock

Biotech

Health Care

Johnson & Johnson's New 'Compelling Data' Shows Sustained Symptom Improvement In Muscular Disease Patients

Press Releases

Myomo to Participate in the 2024 Maxim Healthcare Virtual Summit

Myomo to Report Third Quarter Financial Results on November 6, 2024

Myomo Announces First Private Payer Contracts for MyoPro In-network Coverage

Myomo Reports Record Third Quarter Financial and Operating Results

Myomo, Inc. Announces Proposed Public Offering of Common Stock

Myomo, Inc. Prices $15.0 Million Public Offering of Common Stock

Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

Myomo to Report Fourth Quarter 2024 Financial Results on March 10

Myomo's Fourth Quarter Financial Results Feature Record Revenue of $12.1 Million

Comments

Myomo

Notizie

Ultime notizie per Myomo (AMEX:MYO) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO